A single 40-mg Amjevita pen device will be available at two prices: a list price (wholesale acquisition cost) of $1557.59, 55% below the current Humira list price, and a list price of $3288.24 ...

Amjevita (adalimumab-atto) is a prescription drug that’s used to manage certain inflammatory conditions, such as rheumatoid arthritis and plaque psoriasis. Amjevita comes as a liquid solution ...

Amgen’s long-awaited Humira biosimilar, Amjevita, has finally hit the market. After years of sitting on the biosimilar, which won an FDA approval in 2016, Amgen is ready to make waves.

Read the Medication Guide and Instructions for Use provided by your pharmacist before you start using adalimumab and each time you get a refill. Ask your health care professional how to prepare ...

Amgen said its drug, Amjevita, or adalimumab-atto, will have two list prices -- $3,288 and $1,557 per 40 milligram pen device for a two-week supply -- representing a discount of 5% and 55% to ...

The new drug, Amjevita, will be sold at a list price from $1,558 to $3,288 for a 40 milligram, two-week supply of the injectable drug, Amgen said, representing discounts of 5% or 55% from Humira's ...

Amjevita is a prescription drug used to treat certain inflammatory conditions, including rheumatoid arthritis. Learn about the common, mild, and serious side effects it can cause and how to manage ...

Despite being approved in 2016, the first adalimumab (Humira) biosimilar, Amjevita from Amgen, has finally launched in the United States.All of the adalimumab biosimilars had reached settlement ...

At the end of January, Amgen (AMGN-1.03%) celebrated the U.S. launch of its biosimilar Amjevita to AbbVie's (ABBV 2.64%) star immunology drug called Humira. Amgen's Amjevita received approval from ...

Amgen Inc on Tuesday said it was launching Amjevita, or adalimumab-atto, a biosimilar version of AbbVie Inc's big selling arthritis treatment Humira, the first such biosimilar competition for the ...

Humira has been the world’s best selling medicine since it arrived on the market in 2002. Now, it is finally getting competition with the release of Amgen’s biosimilar drug, Amjevita. Humira ...